CPNP 2008 Annual Meeting

Download the 2008 Annual Meeting Brochure

Overall Educational Goals and Specific Learning Objectives

  • Discuss how inclusion and exclusion criteria can affect study results and how to determine if a patient is an appropriate candidate for study enrollment.
  • Recognize issues associated with clinician rating including interrater reliability, interview quality, and rater bias and how these can impact study results.
  • Discuss the role of trauma, rating scales, and pharmacotherapy options in PTSD.
  • Summarize evidence indicating that people in the arts have a high rate of mood disorders, relating what we know about psychological, environmental and genetic factors.
  • Compare and contrast different pharmacologic approaches for the treatment of neuropathic pain.
  • Discuss the pharmacology of recently approved antiepileptic drugs for the treatment of seizure disorders.
  • Identify biomarkers and signs and symptoms of Alzheimer's disease and critically evaluate the efficacy of current and emerging therapeutic options for patients at each stage of Alzheimer's disease.
  • Describe the study design, rationale, and study endpoints of the specific landmark clinical trials.
  • Analyze the incidence of adverse effects across the agents utilized in landmark trials, and their relationship to discontinuation, dropout, or relapse rates.
  • Identify substance abuse/withdrawal and issues related to treatment and adherence in elderly patients.
  • Evaluate the risks and benefits of individual psychotropic drug classes in pregnancy and lactation.
  • Provide counseling recommendations for the pregnant or lactating patient.
  • Discuss the limitations in identifying risk in clinical trials for rare safety signals, providing recent examples illustrating the FDA's perspective on incorporating this new safety data into product labeling.
  • Provide example of, and discuss future issues related to, pharmacoeconomic studies in psychiatry.
  • Develop pharmacotherapy plans for anxiety disorders in children and adolescents.
  • Detect and manage pharmacotherapy in women with bipolar disorder throughout the lifespan.
  • Assess ethical issues related to the management of agitation.
  • Present the data evaluating lithium’s neuroprotective effect and its promotion of resilience and neuronal plasticity.
  • Describe mechanisms of action that are most promising for the future treatment of anxiety disorders and insomnia, listing compounds in late phase research trials.

Target Audience

If you are a pharmacist, practitioner, educator, scientist, administrator, student, resident, fellow, nurse practitioner or other healthcare professional involved in the pharmaceutical care of psychiatric and/or neurological patients, we invite you to attend the CPNP Annual Meeting. Through this meeting, practitioners at all levels in the areas of neurology and psychiatry can grow and improve in their specialty areas. The Annual Meeting also benefits those pharmacists who play an ever-increasing role in assuring appropriate drug use, providing overall pharmacotherapy management and enhancing positive outcomes. More importantly, the Annual Meeting provides an opportunity for all attendees to interact and share experiences regarding their areas of common interest.

Continuing Education Credit

The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The 2008 Annual Meeting will provide up to 14.5 contact hours of continuing education credit from CPNP approved programming. The pre-meeting workshop is provided for an additional 3.0 hours. Additional ACPE hours will be available through five industry supported satellite symposia.

Participants must verify their attendance at the programming and complete evaluations and self-assessment questions in order to request ACPE credit. Statements of credit will be retrieved by participants online on the CPNP website within one month following the event.

CME for the CPNP Annual Meeting is sponsored by The University of Arizona College of Medicine at the Arizona Health Sciences Center. This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the Joint sponsorship of The University of Arizona College of Medicine at the Arizona Health Sciences Center and College of Psychiatric and Neurologic Pharmacists. The University of Arizona College of Medicine at the Arizona Health Sciences Center is accredited by the ACCME to provide continuing medical education for physicians.

The University of Arizona College of Medicine at the Arizona Health Sciences Center designates this educational activity for a maximum of 17.5 AMA PRA Category 1 Credit(s)™ (14.5 for the general conference and an additional 3.0 for the Pre Meeting Workshop). Physicians should only claim credit commensurate with the extent of their participation in the activity.